In simple words: The doctor or nurse gives a second or later dose of the COVID-19 medicine casirivimab and imdevimab. This can be done through an IV drip or a shot under the skin. They watch the patient for an hour afterward.

This HCPCS code (M0240) represents the administration of a subsequent repeat dose of casirivimab and imdevimab via intravenous (IV) infusion or subcutaneous injection.The procedure includes the preparation of the solution (bringing to correct temperature, vial inspection, dilution for infusion or withdrawal into syringes for subcutaneous injection), administration of the medication (needle/catheter insertion, infusion setup and initiation, or subcutaneous injection), and post-administration monitoring (typically one hour).The recommended dosage for a subsequent dose is 300 mg of casirivimab and 300 mg of imdevimab.This is typically used as post-exposure prophylaxis (PEP) for individuals at risk of severe COVID-19.

Example 1: A patient, previously treated with casirivimab and imdevimab, experiences ongoing exposure to COVID-19 and requires a subsequent repeat dose for continued protection. The physician orders M0240 to administer the medication via IV infusion in an outpatient setting., An immunocompromised patient, post initial casirivimab and imdevimab treatment, shows persistent high viral load and exhibits symptoms indicating ongoing infection. The physician orders M0240 to administer the medicine via subcutaneous injection, opting for this route due to patient preference., A patient who received an initial dose of casirivimab and imdevimab in a hospital setting needs a repeat dose as part of a post-exposure prophylaxis regimen. This is provided in an urgent care setting, requiring the administration to be done by IV infusion per M0240.

* Physician order specifying casirivimab and imdevimab administration.* Documentation of previous casirivimab and imdevimab administration.* Patient’s medical history, including risk factors for severe COVID-19.* Details on route of administration (IV infusion or subcutaneous injection).* Documentation of medication preparation and administration.* Charting of patient's vital signs and condition before, during, and after administration.* Notes on any adverse reactions or complications.* Documentation of post-administration observation period (at least 1 hour).

** This code is specific to the administration of subsequent repeat doses of casirivimab and imdevimab.Separate codes may apply for the initial dose or for the supply of the medication.